SCHEMBL1367048

SCHEMBL1367048

COc1cccc2[nH]c(=O)c(C(=O)c3cc4c(OC)cccc4[nH]c3=O)cc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.59
MEN1 O00255 5/20 0.59
RAB9A P51151 4/20 0.59
NPC1 O15118 3/20 0.59
ATM Q13315 1/20 0.59
FLT3 P36888 2/20 0.57
MTNR1A P48039 5/20 0.52
MTNR1B P49286 5/20 0.52
HRH4 Q9H3N8 1/20 0.49
RCE1 Q9Y256 1/20 0.47
ABCG2 Q9UNQ0 1/20 0.47
POLB P06746 1/20 0.46
IDO1 P14902 1/20 0.46
GFER P55789 1/20 0.46
KDM4E B2RXH2 2/20 0.44
MAPT P10636 2/20 0.44
LMNA P02545 1/20 0.44
PKM P14618 1/20 0.44
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12969925 0.80 ATM (0.64) KMT2AMEN1RAB9ANPC1ATM
SCHEMBL31550010 0.78 MEN1 (0.62) KMT2AMEN1RAB9ANPC1ATM
SCHEMBL831150 0.76 KMT2A (0.59) KMT2AMEN1RAB9ANPC1ATM
SCHEMBL29414307 0.75 FLT3 (0.68) KMT2AMEN1RAB9ANPC1ATM
SCHEMBL913914 0.75 FLT3 (0.68) KMT2AMEN1RAB9ANPC1ATM
SCHEMBL7979026 0.75 FLT3 (0.68) KMT2AMEN1RAB9ANPC1ATM
SCHEMBL24447653 0.74 FLT3 (0.66) KMT2AMEN1RAB9ANPC1ATM
SCHEMBL217459 0.74 FLT3 (0.66) KMT2AMEN1RAB9ANPC1FLT3
SCHEMBL30310403 0.74 FLT3 (0.66) KMT2AMEN1RAB9ANPC1ATM
SCHEMBL24113092 0.74 FLT3 (0.66) KMT2AMEN1RAB9ANPC1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2009-11-05 US claimed
WO-2006132947-A2 3-ACYL COUMARINS, THIOCHROMONES AND QUINOLONES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2006-12-14 WO claimed
US-8067461-B2 3-acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2011-11-29 US disclosed
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2009-11-05 US disclosed
WO-2006132947-A2 3-ACYL COUMARINS, THIOCHROMONES AND QUINOLONES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2006-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof NQO2, NQO1, HCCS KMT2A 1726/4885MEN1 1108/4885RAB9A 1991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.